Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

NCT00004228 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 393

Last updated 2019-08-06

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma.

PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.

Conditions

Interventions

DRUG

asparaginase

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

cytarabine

Given IV

DRUG

daunorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

mercaptopurine

Given IV

DRUG

methotrexate

Given IV

DRUG

prednisone

Given IV

DRUG

thioguanine

Given PO

DRUG

vincristine sulfate

Given IV

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Minnie Abromowitch, MD · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2008-08-31
Completion
2015-03-31

Countries

  • United States
  • Australia
  • Canada
  • Puerto Rico
  • Switzerland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004228 on ClinicalTrials.gov